Johnson & Johnson’s new therapy to treat resistant depression, Spravato, is overpriced, according to the Institute for Clinical and Economic Review (ICER), though it could provide a “comparable, small, or substantial net health benefit” for patients.
According to a FiercePharma report, the drug’s price before rebates and discounts is between $4,720 and $6,785 for the first month. Following treatments would cost between $2,360 to $3,540.
ICER estimated the drug to cost about $198,000 per quality-adjusted life year, but should cost between $50,000-$150,000.
The treatment, according to the report, must be administered to a doctor’s office. J&J reports some 800 sites have been cleared to administer the treatment.
To read the full report on FiercePharma, click here.